Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Chimeric Therapeutics - Clinical milestones for 2024 & 2023 successes highlighted (ASX:CHM)

-- Reported positive preliminary data for CHM 1101 in heavily pretreated glioblastoma patients, confirming advancement to next phase of CHM 1101 development -- FDA IND clearance for CHM 2101 enabli...read more

Careteq - Receipt of ATO Position Paper (ASX:CTQ)

Careteq Limited (ASX: CTQ) (Careteq) advises that it has received an audit position paper (Position Paper) from the Australian Taxation Office (ATO). The Position Paper relates to Careteq's R&am...read more

Carbonxt Group - HY24 Results Announcement (ASX:CG1)

Carbonxt Group Ltd (ASX:CG1) (“Carbonxt” or “the Company”) has released its Half-year report for the half-year ending 31 December 2023 and provides the following update on th...read more

Carbonxt Group - Half Yearly Report and Accounts (ASX:CG1)

To view the report, download the attached PDF.

Chimeric Therapeutics - Half Yearly Report and Accounts (ASX:CHM)

To view the report, download the attached PDF.

CARETEQ - Appendix 4D & Half Year Results (ASX:CTQ)

Careteq Limited (ASX: CTQ, “Careteq” or the “Company”), a leader in providing cloud-based assistive living technology solutions and medication management and adherence servic...read more

Careteq - Half Year Results Presentation (ASX:CTQ)

To view the presentation, download the attached PDF.

Chimeric Therapeutics - 1st patient treated in ADVENT-AML Phase 1b clinical trial (ASX:CHM)

ADVENT-AML is the first clinical trial to evaluate NK cell therapy in combination with the current standard of care for Acute Myeloid Leukemia (AML) patients The trial, no...read more

Carbonxt Group - December 2023 Quarterly Activities Report (ASX:CG1)

Highlights -- Construction of the flagship Activated Carbon production facility in Kentucky, USA continues to progress well, with the focus now turning to commissioning activities and near-term s...read more

Carbonxt Group - Appendix 4C (ASX:CG1)

To view the appendix, download the attached PDF.

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Sydney, Australia, 31 January 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its...read more

Careteq - Q2-FY24 activities report & appendix 4C (ASX:CTQ)

Careteq Limited (ASX: CTQ) (“Careteq” or “the Company”), a leading innovator in remote monitoring and healthcare technology, is pleased to provide the following quarterly upd...read more

Chimeric Therapeutics - Placement of Entitlement Offer Shortfall (ASX:CHM)

-- Placement of Entitlement Offer Shortfall of approx. $3.20m from institutional and sophisticated investors -- Takes the total amount subscribed under the entitlement offer and entitlement offer s...read more

Chimeric Therapeutics - ADVENT-AML Phase 1B clinical trial open to enrolment (ASX:CHM)

-- ADVENT-AML (CHM 0201 + Azacitidine + Venetoclax) Phase 1B clinical trial now open to enrollment at The University of Texas MD Anderson Cancer Center -- Enrolment open to patients with relapsed /...read more

Chimeric Therapeutics receives $7.36M R&D tax incentive (ASX:CHM)

Sydney, Australia, 10 January 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell, is pleased announce it has received a research...read more

Viewing: 1 - 15 of 200 Previous | Next